Gerhard Heil

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

Richard F. Schlenk, Konstanze Döhner, Jürgen Krauter et al. · New England Journal of Medicine · 2008 · 1.6K citations

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Lymphoid Neoplasia, Rituximab Versus Chop, Oncology +10

Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults

D. Hoelzer, E. Thiel, H. Löffler et al. · Blood · 1988 · 588 citations · Full text

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle, Hanno Riess, Jens Stieler et al. · Journal of Clinical Oncology · 2014 · 476 citations

Incidence and Prognostic Influence of <i>DNMT3A</i> Mutations in Acute Myeloid Leukemia

Felicitas Thol, Frédérik Damm, Andrea Lüdeking et al. · Journal of Clinical Oncology · 2011 · 375 citations · Full text